Retrospective Study of Hepatitis C Virus Genotypes and its Association with Lymphoma
DOI:
https://doi.org/10.6000/1929-2279.2014.03.03.2Keywords:
HCV genotypes, HCV associated lymphomas, HCV.Abstract
Hepatitis C virus (HCV) involves both the liver and extra hepatic organs. The aim of this study was to retrospectively evaluate the association between HCV genotypes and lymphomas.
Lymphoma cases were retrieved from our surgical pathology and hematopathology archives from January 2005 to April 2012. Patients who had positive HCV serology with subsequent viral genotyping were selected. Patients with positive Human immunodeficiency virus (HIV)serology were excluded.
We identified 17 lymphoma cases with associated HCV infection. Eleven out of 14 (79%) patients had genotype 1 HCV. Diffuse large B cell lymphoma (DLBCL) was the most common lymphoma (6 out of 17 cases) and all cases of DLBCL had genotype 1. Genotype 2 was detected in only three patients (21%) with the diagnoses of follicular lymphoma, splenic marginal zone lymphoma, and classical Hodgkin lymphoma (CHL). CHL was diagnosed in three cases and peripheral T-cell lymphoma in one case.Twelve of 17 (71%) patients were incarcerated in the Texas Department of Criminal Justice system. All 11 genotype 1 patients were male, 4 of 11 (36%) were African American, 4 of 11 (36%) were Caucasian and 3 of 11 (27%) were Hispanic.We concluded that HCV genotype 1 was more common than genotype 2 while no other genotype was detected.
References
Clarke B. Molecular virology of hepatitis C virus. J Gen Virol 1997; 78: 2397-410.
Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41. http://dx.doi.org/10.1126/science.282.5390.938
Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Ann Rev Immunol 1998; 16: 89-109. http://dx.doi.org/10.1146/annurev.immunol.16.1.89
Ghany MG, Strader DB, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74. http://dx.doi.org/10.1002/hep.22759
Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84. http://dx.doi.org/10.1053/j.gastro.2006.06.007
Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73. http://dx.doi.org/10.1002/hep.20819
Yee HS, Chang MF, Pocha C, et al. Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012; 107: 669-89. http://dx.doi.org/10.1038/ajg.2012.48
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52. http://dx.doi.org/10.1056/NEJM200107053450107
Rosen HR. Chronic hepatitis C infection. N Engl J Med 2011; 364: 2429-38. http://dx.doi.org/10.1056/NEJMcp1006613
Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol 1994; 88: 392-4. http://dx.doi.org/10.1111/j.1365-2141.1994.tb05036.x
Pozzato G, Mazzaro C, Crovatto M, et al. Low grade malignant lymphoma, hepatitis C virus infection and mixed cryoglobulinemia. Blood 1994; 84: 3047-53.
Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italianmulticenter case-control study. Blood 2003; 102: 996-9. http://dx.doi.org/10.1182/blood-2002-10-3230
Duberg AS, Nordstrom M, Torner A, et al. Non-Hodgkin’s lymphoma and other non-hepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005; 41: 652-9. http://dx.doi.org/10.1002/hep.20608
Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008; 17: 3069-75. http://dx.doi.org/10.1158/1055-9965.EPI-08-0408
Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006; 15: 2078-85. http://dx.doi.org/10.1158/1055-9965.EPI-06-0308
Pellicelli AM, Marignani M, Zoli V, et al. Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. World J Hepatol 2011; 3: 278-84. http://dx.doi.org/10.4254/wjh.v3.i11.278
Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23: 695-9. http://dx.doi.org/10.1002/hep.510230406
Prati D, Capelli C, Zanella A, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 1996; 110: 178-83. http://dx.doi.org/10.1053/gast.1996.v110.pm8536854
Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 2625-30.
Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117: 1792-8. http://dx.doi.org/10.1182/blood-2010-06-275818
Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034-4. http://dx.doi.org/10.1182/blood-2005-09-3679
Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter casecontrol study EPILYMPH. Gastroenterology 2006; 131: 1879-86. http://dx.doi.org/10.1053/j.gastro.2006.09.019
de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-8. http://dx.doi.org/10.1016/j.cgh.2008.02.011
Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012; 51: 2745-7. http://dx.doi.org/10.2169/internalmedicine.51.8404
Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94. http://dx.doi.org/10.1056/NEJMoa013376
Vallisa D, Bernuzzi P, Arcaini L, et al. Role of antihepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: A multicenter Italian experience. J Clin Oncol 2005; 23: 468-73. http://dx.doi.org/10.1200/JCO.2005.06.008
Baillargeon J, Black SA, Leach CT, et al. The infectious disease profile of Texas prison inmates. Prev Med 2004; 38: 607-12. http://dx.doi.org/10.1016/j.ypmed.2003.11.020
Baillargeon J, Soloway RD, Paar D, et al. End-stage liver disease in a state prison population. Ann Epidemiol 2007; 17: 808-13. http://dx.doi.org/10.1016/j.annepidem.2007.04.005